The historical rank and industry rank for Luye Pharma Group's FCF Margin % or its related term are showing as below:
HKSE:02186'
s FCF Margin % Range Over the Past 10 Years
Min: -27.81 Med: -0.89 Max: 28.12
Current: 28.12
During the past 13 years, the highest FCF Margin % of Luye Pharma Group was 28.12%. The lowest was -27.81%. And the median was -0.89%.
HKSE:02186's FCF Margin % is ranked better than 95.21% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs HKSE:02186: 28.12
Luye Pharma Group FCF Margin % Related Terms
Luye Pharma Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (HKSE:02186) has a FCF Margin % of -0.04% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Luye Pharma Group and its competitors. According to the industry distribution chart, Luye Pharma Group ranks #46 out of 960 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Luye Pharma Group's FCF Margin % too high?
Luye Pharma Group's current FCF Margin % is -0.04%. Based on the distribution chart, Luye Pharma Group ranks #46 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #46 out of 960 companies for FCF Margin %. This places Luye Pharma Group in the top 5% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current FCF Margin % is -0.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (HKSE:02186) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.14, compared to a current price of HK$2.03 — trading 35.4% below its estimated fair value. The current FCF Margin % is -0.04%. Luye Pharma Group's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Luye Pharma Group (HKSE:02186), the current FCF Margin % is -0.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (HKSE:02186) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of HK$2.03 is trading 35.4% below its estimated GF Value™ of HK$3.14.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for HKSE:02186:
FCF Margin %: -0.04%
GF Value™: HK$3.14 vs. price of HK$2.03 (35.4% below fair value)
No single metric tells the full story. See the HKSE:02186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
81GF Score
Get the complete analysis for HKSE:02186
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02186 has been successfully added to your 
